Cardiovascular and renal safety outcomes of hypoxia-inducible factor prolyl-hydroxylase inhibitor roxadustat for anemia patients with chronic kidney disease: a systematic review and meta-analysis

References

• Wu T, Qi Y, Ma S, et al. Efficacy of roxadustat on anemia and residual renal function in patients new to peritoneal dialysis. Ren Fail. 2022;44(1):1–18. doi:10.1080/0886022X.2022.2050754.
   Web of Science ®Google Scholar
• Amaral S, Hwang W, Fivush B, et al. Association of mortality and hospitalization with achievement of adult hemoglobin targets in adolescents maintained on hemodialysis. J Am Soc Nephrol. 2006;17(10):2878–2885. doi:10.1681/ASN.2005111215.
   PubMed Web of Science ®Google Scholar
• Matteucci MC, Wühl E, Picca S, et al. Left ventricular geometry in children with mild to moderate chronic renal insufficiency. J Am Soc Nephrol. 2006;17(1):218–226. doi:10.1681/ASN.2005030276.
   PubMed Web of Science ®Google Scholar
• Kular D, Macdougall IC. HIF stabilizers in the management of renal anemia: from bench to bedside to pediatrics. Pediatr Nephrol. 2019;34(3):365–378. doi:10.1007/s00467-017-3849-3.
   PubMed Web of Science ®Google Scholar
• Kalantar-Zadeh K, Lee GH, Miller JE, et al. Predictors of hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis patients. Am J Kidney Dis. 2009;53(5):823–834. doi:10.1053/j.ajkd.2008.12.040.
   PubMed Web of Science ®Google Scholar
• Koulouridis I, Alfayez M, Trikalinos TA, et al. Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis. Am J Kidney Dis. 2013;61(1):44–56. doi:10.1053/j.ajkd.2012.07.014.
   PubMed Web of Science ®Google Scholar
• Szczech LA, Barnhart HX, Inrig JK, et al. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int. 2008;74(6):791–798. doi:10.1038/ki.2008.295.
   PubMed Web of Science ®Google Scholar
• Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339(9):584–590. doi:10.1056/NEJM199808273390903.
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361(21):2019–2032. doi:10.1056/NEJMoa0907845.
   PubMed Web of Science ®Google Scholar
• Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355(20):2085–2098. doi:10.1056/NEJMoa065485.
   PubMed Web of Science ®Google Scholar
• Fishbane S, Schiller B, Locatelli F, et al. Peginesatide in patients with anemia undergoing hemodialysis. N Engl J Med. 2013;368(4):307–319. doi:10.1056/NEJMoa1203165.
   PubMed Web of Science ®Google Scholar
• Manns BJ, Tonelli M. The new FDA labeling for ESA–implications for patients and providers. Clin J Am Soc Nephrol. 2012;7(2):348–353. doi:10.2215/CJN.09960911.
   PubMed Web of Science ®Google Scholar
• Crathorne L, Huxley N, Haasova M, et al. The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer treatment-induced anaemia (including review of technology appraisal no. 142): a systematic review and economic model. v-vi. Health Technol Assess. 2016;20(13):1–588. doi:10.3310/hta20130.
   Web of Science ®Google Scholar
• Schmid H. Cost-effectiveness of continuous erythropoietin receptor activator in anemia. Clinicoecon Outcomes Res. 2014;6:319–330. doi:10.2147/CEOR.S46930.
   PubMedGoogle Scholar
• Rostoker G. When should iron supplementation in dialysis patients be avoided, minimized or withdrawn? Semin Dial. 2019;32(1):22–29. doi:10.1111/sdi.12732.
   PubMed Web of Science ®Google Scholar
• Besarab A, Provenzano R, Hertel J, et al. Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients. Nephrol Dial Transplant. 2015;30(10):1665–1673. doi:10.1093/ndt/gfv302.
   PubMed Web of Science ®Google Scholar
• Chen N, Qian J, Chen J, et al. Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China. Nephrol Dial Transplant. 2017;32(8):1373–1386. doi:10.1093/ndt/gfx011.
   PubMed Web of Science ®Google Scholar
• Chen N, Hao C, Liu BC, et al. Roxadustat treatment for anemia in patients undergoing long-term dialysis. N Engl J Med. 2019;381(11):1011–1022. doi:10.1056/NEJMoa1901713.
   PubMed Web of Science ®Google Scholar
• Chen N, Hao C, Peng X, et al. Roxadustat for anemia in patients with kidney disease not receiving dialysis. N Engl J Med. 2019;381(11):1001–1010. doi:10.1056/NEJMoa1813599.
   PubMed Web of Science ®Google Scholar
• Akizawa T, Iwasaki M, Yamaguchi Y, et al. Phase 3, randomized, Double-Blind, Active-Comparator (darbepoetin alfa) study of oral roxadustat in CKD patients with anemia on hemodialysis in Japan. J Am Soc Nephrol. 2020;31(7):1628–1639. doi:10.1681/ASN.2019060623.
   PubMed Web of Science ®Google Scholar
• Akizawa T, Yamaguchi Y, Otsuka T, et al. A phase 3, multicenter, randomized, two-Arm, Open-Label study of intermittent oral dosing of roxadustat for the treatment of anemia in japanese erythropoiesis-stimulating Agent-Naïve chronic kidney disease patients not on dialysis. Nephron. 2020;144(8):372–382. doi:10.1159/000508100.
   PubMed Web of Science ®Google Scholar
• Barratt J, Andric B, Tataradze A, et al. Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a phase 3, randomized, open-label, active-controlled study (DOLOMITES). Nephrol Dial Transplant. 2021;36(9):1616–1628. doi:10.1093/ndt/gfab191.
   PubMed Web of Science ®Google Scholar
• Csiky B, Schömig M, Esposito C, et al. Roxadustat for the maintenance treatment of anemia in patients with End-Stage kidney disease on stable dialysis: a european phase 3, randomized, Open-Label, Active-Controlled study (PYRENEES). Adv Ther. 2021;38(10):5361–5380. doi:10.1007/s12325-021-01904-6.
   PubMed Web of Science ®Google Scholar
• Akizawa T, Iwasaki M, Otsuka T, et al. Roxadustat treatment of chronic kidney disease-associated anemia in japanese patients not on dialysis: a phase 2, randomized, Double-Blind, placebo-controlled trial. Adv Ther. 2019;36(6):1438–1454. doi:10.1007/s12325-019-00943-4.
   PubMed Web of Science ®Google Scholar
• Akizawa T, Iwasaki M, Otsuka T, et al. Phase 3 study of roxadustat to treat anemia in non-dialysis-Dependant CKD. Kidney Int Rep. 2021;6(7):1810–1828. doi:10.1016/j.ekir.2021.04.003.
   PubMed Web of Science ®Google Scholar
• Hou YP, Mao XY, Wang C, et al. Roxadustat treatment for anemia in peritoneal dialysis patients: a randomized controlled trial. J Formos Med Assoc. 2022;121(2):529–538. doi:10.1016/j.jfma.2021.06.004.
   PubMed Web of Science ®Google Scholar
• Shutov E, Sułowicz W, Esposito C, et al. Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: a phase 3, randomized, double-blind, placebo-controlled study (ALPS). Nephrol Dial Transplant. 2021;36(9):1629–1639. doi:10.1093/ndt/gfab057.
   PubMed Web of Science ®Google Scholar
• Fishbane S, El-Shahawy MA, Pecoits-Filho R, et al. Roxadustat for treating anemia in patients with CKD not on dialysis: results from a randomized phase 3 study. J Am Soc Nephrol. 2021;32(3):737–755. doi:10.1681/ASN.2020081150.
   PubMed Web of Science ®Google Scholar
• Fishbane S, Pollock CA, El-Shahawy M, et al. Roxadustat versus epoetin alfa for treating anemia in patients with chronic kidney disease on dialysis: results from the randomized phase 3 ROCKIES study. J Am Soc Nephrol. 2022;33(4):850–866. doi:10.1681/ASN.2020111638.
   PubMed Web of Science ®Google Scholar
• Coyne DW, Roger SD, Shin SK, et al. Roxadustat for CKD-related anemia in non-dialysis patients. Kidney Int Rep. 2021;6(3):624–635. doi:10.1016/j.ekir.2020.11.034.
   PubMed Web of Science ®Google Scholar
• Provenzano R, Shutov E, Eremeeva L, et al. Roxadustat for anemia in patients with end-stage renal disease incident to dialysis. Nephrol Dial Transplant. 2021;36(9):1717–1730. doi:10.1093/ndt/gfab051.
   PubMed Web of Science ®Google Scholar
• Charytan C, Manllo-Karim R, Martin ER, et al. A randomized trial of roxadustat in anemia of kidney failure: SIERRAS study. Kidney Int Rep. 2021;6(7):1829–1839. doi:10.1016/j.ekir.2021.04.007.
   PubMed Web of Science ®Google Scholar
• Thompson S, James M, Wiebe N, et al. Cause of death in patients with reduced kidney function. J Am Soc Nephrol. 2015;26(10):2504–2511. doi:10.1681/ASN.2014070714.
   PubMed Web of Science ®Google Scholar
• Wen Y, Xu Y, Tian H, et al. Cardiovascular protective effects of oral hypoxia inducible factor prolyl hydroxylase inhibitor roxadustat in the treatment of type 4 Cardiorenal-Anemia syndrome: protocol of a randomized controlled trial. Front Med (Lausanne). 2022;9:783387. doi:10.3389/fmed.2022.783387.
   PubMed Web of Science ®Google Scholar
• Swedberg K, Young JB, Anand IS, et al. Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med. 2013;368(13):1210–1219. doi:10.1056/NEJMoa1214865.
   PubMed Web of Science ®Google Scholar
• Chang WT, Lo YC, Gao ZH, et al. Evidence for the capability of roxadustat (FG-4592), an oral HIF prolyl-hydroxylase inhibitor, to perturb membrane ionic currents: an unidentified yet important action. Int J Mol Sci. 2019;20(23):6027. doi:10.3390/ijms20236027.
   PubMed Web of Science ®Google Scholar
• Tang M, Zhu C, Yan T, et al. Safe and effective treatment for anemic patients with chronic kidney disease: an updated systematic review and meta-analysis on roxadustat. Front Pharmacol. 2021;12:658079. doi:10.3389/fphar.2021.658079.
   PubMed Web of Science ®Google Scholar
• Provenzano R, Besarab A, Wright S, et al. Roxadustat (FG-4592) versus epoetin alfa for anemia in patients receiving maintenance hemodialysis: a phase 2, randomized, 6- to 19-Week, Open-Label, Active-Comparator, dose-Ranging, safety and exploratory efficacy study. Am J Kidney Dis. 2016;67(6):912–924. doi:10.1053/j.ajkd.2015.12.020.
   PubMed Web of Science ®Google Scholar
• Gupta N, Wish JB. Hypoxia-Inducible factor prolyl hydroxylase inhibitors: a potential new treatment for anemia in patients with CKD. Am J Kidney Dis. 2017;69(6):815–826. doi:10.1053/j.ajkd.2016.12.011.
   PubMed Web of Science ®Google Scholar
• Miki K, Nakamura Y, Yokoyama T, et al. Therapeutic effect of roxadustat on patients with posttransplant anemia. Transplant Proc. 2022;54(3):671–677. doi:10.1016/j.transproceed.2022.02.004.
   PubMed Web of Science ®Google Scholar
• Hirai K, Kaneko S, Minato S, et al. Effects of roxadustat on anemia, iron metabolism, and lipid metabolism in patients with non-dialysis chronic kidney disease. Front Med (Lausanne). 2023;10:1071342. doi:10.3389/fmed.2023.1071342.
   PubMed Web of Science ®Google Scholar
• Nguyen AD, McDonald JG, Bruick RK, et al. Hypoxia stimulates degradation of 3-hydroxy-3-methylglutaryl-coenzyme a reductase through accumulation of lanosterol and hypoxia-inducible factor-mediated induction of insigs. J Biol Chem. 2007;282(37):27436–27446. doi:10.1074/jbc.M704976200.
   PubMed Web of Science ®Google Scholar
• Fang T, Ma C, Zhang Z, et al. Roxadustat, a HIF-PHD inhibitor with exploitable potential on diabetes-related complications. Front Pharmacol. 2023;14:1088288. doi:10.3389/fphar.2023.1088288.
   PubMed Web of Science ®Google Scholar
• Zhang X, Zhang Y, Wang P, et al. Adipocyte hypoxia-inducible factor 2α suppresses atherosclerosis by promoting adipose ceramide catabolism. Cell Metab. 2019;30(5):937–951.e935. doi:10.1016/j.cmet.2019.09.016.
   PubMed Web of Science ®Google Scholar
• Deguchi H, Ikeda M, Ide T, et al. Roxadustat markedly reduces myocardial ischemia reperfusion injury in mice. Circ J. 2020;84(6):1028–1033. doi:10.1253/circj.CJ-19-1039.
   PubMed Web of Science ®Google Scholar
• Ma X, Dong Z, Liu J, et al. β-Hydroxybutyrate exacerbates hypoxic injury by inhibiting HIF-1α-dependent glycolysis in Cardiomyocytes-Adding fuel to the fire? Cardiovasc Drugs Ther. 2022;36(3):383–397. doi:10.1007/s10557-021-07267-y.
   PubMed Web of Science ®Google Scholar
• Provenzano R, Szczech L, Leong R, et al. Efficacy and cardiovascular safety of roxadustat for treatment of anemia in patients with non-dialysis-dependent CKD: pooled results of three randomized clinical trials. Clin J Am Soc Nephrol. 2021;16(8):1190–1200. doi:10.2215/CJN.16191020.
   PubMed Web of Science ®Google Scholar
• Hölscher M, Schäfer K, Krull S, et al. Unfavourable consequences of chronic cardiac HIF-1α stabilization. Cardiovasc Res. 2012;94(1):77–86. doi:10.1093/cvr/cvs014.
   PubMed Web of Science ®Google Scholar
• Janbandhu V, Tallapragada V, Patrick R, et al. Hif-1a suppresses ROS-induced proliferation of cardiac fibroblasts following myocardial infarction. Cell Stem Cell. 2022;29(2):281–297.e212. doi:10.1016/j.stem.2021.10.009.
   PubMed Web of Science ®Google Scholar
• Miao AF, Liang JX, Yao L, et al. Hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) protects against renal ischemia/reperfusion injury by inhibiting inflammation. Ren Fail. 2021;43(1):803–810. doi:10.1080/0886022X.2021.1915801.
   PubMed Web of Science ®Google Scholar
• Yang H, Wu Y, Cheng M, et al. Roxadustat (FG-4592) protects against ischaemia-induced acute kidney injury via improving CD73 and decreasing AIM2 inflammasome activation. Nephrol Dial Transplant. 2023;38(4):858–875. doi:10.1093/ndt/gfac308.
   PubMed Web of Science ®Google Scholar
• Yu J, Wang S, Shi W, et al. Roxadustat prevents ang II hypertension by targeting angiotensin receptors and eNOS. JCI Insight. 2021;6(18):6. doi:10.1172/jci.insight.133690.
   Web of Science ®Google Scholar
• Feng X, Wang S, Sun Z, et al. Ferroptosis enhanced diabetic renal tubular injury via HIF-1α/HO-1 pathway in db/db mice. Front Endocrinol (Lausanne). 2021;12:626390. doi:10.3389/fendo.2021.626390.
   PubMed Web of Science ®Google Scholar
• Czock D, Keller F. Clinical pharmacokinetics and pharmacodynamics of roxadustat. Clin Pharmacokinet. 2022;61(3):347–362. doi:10.1007/s40262-021-01095-x.
   PubMed Web of Science ®Google Scholar
• Prchal JT, Gordeuk VR. HIF-2 inhibitor, erythrocytosis, and pulmonary hypertension. Blood. 2021;137(18):2424–2425. doi:10.1182/blood.2020010323.
   PubMed Web of Science ®Google Scholar